27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- iSpecimen Inc (NASDAQ:ISPC) has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research.
- The new suppliers include a cancer-focused biobank in the U.S., which contains a differentiated range of pre-and post-treatment tissue and biofluids across multiple cancer types.
- These samples provide rich genetic, treatment, follow-up, and outcome information.
- Additionally, iSpecimen has retained a European biobank with a vast urine and blood sample inventory from healthy participants aged 45 to 75, collected with participant health data generated from questionnaires and disease diagnoses.
- This biobank contains vital early-onset cancer and cardiovascular disease samples, as well.
- iSpecimen offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers with access to patients and specimens needed for medical discovery.
- Price Action: ISPC shares are up 21.50% at $2.88 during the market session on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!